Sagimet Biosciences (STU:0O2) Other Long Term Assets: €-0.00 Mil (As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.14
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Other Long Term Assets?

Sagimet Biosciences STU:0O2 +1.66% 10 Other Long Term Assets is €-0.00 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Sagimet Biosciences's other long-term assets for the quarter that ended in Mar. 2026 was €-0.00 Mil.

Sagimet Biosciences's quarterly other long-term assets declined from Sep. 2025 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil) but then stayed the same from Dec. 2025 (€-0.00 Mil) to Mar. 2026 (€-0.00 Mil).

Sagimet Biosciences's annual other long-term assets declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€-0.00 Mil) but then increased from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Sagimet Biosciences Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Other Long Term Assets Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial 0.02 0.03 0.00 -0.00 -0.00

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.00 -0.00 -0.00 -0.00
STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €-0.00 Mil mean?
Sagimet Biosciences (STU:0O2) has a Other Long Term Assets of €-0.00 Mil as of Mar. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Other Long Term Assets too high?
Sagimet Biosciences' current Other Long Term Assets is €-0.00 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Other Long Term Assets compare to EDIT and AUTL?
Sagimet Biosciences' Other Long Term Assets of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Other Long Term Assets is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Other Long Term Assets of €-0.00 Mil. The current Other Long Term Assets is €-0.00 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Other Long Term Assets is €-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14
Price